Advertisement

Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma

Published:September 23, 2017DOI:https://doi.org/10.1016/j.ejca.2017.08.026

      Highlights

      • Cytotoxic T-Lymphocytes increase in patients with non-adenocarcinoma, but not with adenocarcinoma.
      • Tumour microenvironment is immunosuppressive in non-smokers with lung adenocarcinoma.
      • CD8+GATA3+ and CD8+FOXP3+ T cells infiltrate adenocarcinoma in non-smokers.
      • M2-like macrophages and effector Tregs increase in non-smokers with adenocarcinoma.
      • Immunosuppressive microenvironment in adenocarcinoma determines poor prognosis.

      Abstract

      We have previously demonstrated that the prognostic significance of tumour-infiltrating CD8+ T cells significantly differs according to histological type and patient smoking habits in non-small cell lung cancer (NSCLC). This work suggested that infiltrating CD8+ T cells may not be activated sufficiently in the immunosuppressive microenvironment in non-smokers with adenocarcinoma. To understand the immunogenic microenvironment in NSCLC, we characterised immune cells comprehensively by performing an immunohistochemical evaluation using an alternative counting method and multicolour staining method (n = 234), and assessed immune-related gene expression by using genetic analytical approaches (n = 58). We found that high infiltration of activated CD8+ T cells expressing interferon gamma (IFN-γ) and granzyme was correlated with postoperative survival in patients with non-adenocarcinoma. On the contrary, CD8+ T-cell accumulation was identified as a worse prognostic factor in patients with adenocarcinoma, particularly in non-smokers. Infiltrating CD8+ T cells were significantly less activated in this microenvironment with high expression of various immunoregulation genes. Potentially immunoregulatory CD8+ FOXP3+ T cells and immunodysfunctional CD8+ GATA3+ T cells were increased in adenocarcinoma of non-smokers. CD4+ FOXP3+ regulatory T cells expressing chemokine receptor-4 (CCR4)- and chemokine ligand (CCL17)-expressing CD163+ M2-like macrophages also accumulated correlatively and significantly in adenocarcinoma of non-smokers. These characteristic immune cells may promote tumour progression possibly by creating an immunosuppressive microenvironment in non-smoking patients with lung adenocarcinoma. Our findings may be helpful for refining the current strategy of personalised immunotherapy including immune-checkpoint blockade therapy for NSCLC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Giroux Leprieur E.
        • Dumenil C.
        • Julie C.
        • Giraud V.
        • Dumoulin J.
        • Labrune S.
        • et al.
        Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges.
        Eur J Cancer. 2017; 78: 16-23
        • Brahmer J.R.
        Harnessing the immune system for the treatment of non-small-cell lung cancer.
        J Clin Oncol. 2013; 31: 1021-1028
        • Brahmer J.
        • Reckamp K.L.
        • Baas P.
        • Crino L.
        • Eberhardt W.E.
        • Poddubskaya E.
        • et al.
        Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.
        N Engl J Med. 2015; 373: 123-135
        • Borghaei H.
        • Paz-Ares L.
        • Horn L.
        • Spigel D.R.
        • Steins M.
        • Ready N.E.
        • et al.
        Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
        N Engl J Med. 2015; 373: 1627-1639
        • Haratani K.
        • Hayashi H.
        • Tanaka T.
        • Kaneda H.
        • Togashi Y.
        • Sakai K.
        • et al.
        Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
        Ann Oncol. 2017 Apr 12; ([Epub ahead of print])https://doi.org/10.1093/annonc/mdx183
        • Rangachari D.
        • VanderLaan P.A.
        • Shea M.
        • Le X.
        • Huberman M.S.
        • Kobayashi S.S.
        • et al.
        Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% expression in lung adenocarcinoma.
        J Thorac Oncol. 2017; 12: 878-883
        • Fridman W.H.
        • Pages F.
        • Sautes-Fridman C.
        • Galon J.
        The immune contexture in human tumours: impact on clinical outcome.
        Nat Rev Cancer. 2012; 12: 298-306
        • Zhuang X.
        • Xia X.
        • Wang C.
        • Gao F.
        • Shan N.
        • Zhang L.
        • et al.
        A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis.
        Appl Immunohistochem Mol Morphol. 2010; 18: 24-28
        • Schalper K.A.
        • Brown J.
        • Carvajal-Hausdorf D.
        • McLaughlin J.
        • Velcheti V.
        • Syrigos K.N.
        • et al.
        Objective measurement and clinical significance of TILs in non-small cell lung cancer.
        J Natl Cancer Inst. 2015; 107
        • Mori M.
        • Ohtani H.
        • Naito Y.
        • Sagawa M.
        • Sato M.
        • Fujimura S.
        • et al.
        Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis.
        Tohoku J Exp Med. 2000; 191: 113-118
        • Wakabayashi O.
        • Yamazaki K.
        • Oizumi S.
        • Hommura F.
        • Kinoshita I.
        • Ogura S.
        • et al.
        CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers.
        Cancer Sci. 2003; 94: 1003-1009
        • Kinoshita T.
        • Muramatsu R.
        • Fujita T.
        • Nagumo H.
        • Sakurai T.
        • Noji S.
        • et al.
        Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer.
        Ann Oncol. 2016; 27: 2117-2123
        • Anitei M.G.
        • Zeitoun G.
        • Mlecnik B.
        • Marliot F.
        • Haicheur N.
        • Todosi A.M.
        • et al.
        Prognostic and predictive values of the immunoscore in patients with rectal cancer.
        Clin Cancer Res. 2014; 20: 1891-1899
        • Galon J.
        • Mlecnik B.
        • Bindea G.
        • Angell H.K.
        • Berger A.
        • Lagorce C.
        • et al.
        Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours.
        J Pathol. 2014; 232: 199-209
        • Kirilovsky A.
        • Marliot F.
        • El Sissy C.
        • Haicheur N.
        • Galon J.
        • Pages F.
        Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.
        Int Immunol. 2016; 28: 373-382
        • Stack E.C.
        • Wang C.
        • Roman K.A.
        • Hoyt C.C.
        Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.
        Methods. 2014; 70: 46-58
        • Tang X.L.
        • Smith T.R.
        • Kumar V.
        Specific control of immunity by regulatory CD8 T cells.
        Cell Mol Immunol. 2005; 2: 11-19
        • Kiniwa Y.
        • Miyahara Y.
        • Wang H.Y.
        • Peng W.
        • Peng G.
        • Wheeler T.M.
        • et al.
        CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
        Clin Cancer Res. 2007; 13: 6947-6958
        • Singer M.
        • Wang C.
        • Cong L.
        • Marjanovic N.D.
        • Kowalczyk M.S.
        • Zhang H.
        • et al.
        A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells.
        Cell. 2016; 166 (1500–1511 e9)
        • Chaput N.
        • Louafi S.
        • Bardier A.
        • Charlotte F.
        • Vaillant J.C.
        • Menegaux F.
        • et al.
        Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
        Gut. 2009; 58: 520-529
        • Sugiyama D.
        • Nishikawa H.
        • Maeda Y.
        • Nishioka M.
        • Tanemura A.
        • Katayama I.
        • et al.
        Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
        Proc Natl Acad Sci USA. 2013; 110: 17945-17950
        • Tanaka A.
        • Sakaguchi S.
        Regulatory T cells in cancer immunotherapy.
        Cell Res. 2017; 27: 109-118
        • Mills C.D.
        • Lenz L.L.
        • Harris R.A.
        A breakthrough: macrophage-directed cancer immunotherapy.
        Cancer Res. 2016; 76: 513-516
        • Gordon S.
        • Martinez F.O.
        Alternative activation of macrophages: mechanism and functions.
        Immunity. 2010; 32: 593-604
        • Hirai M.
        • Kitahara H.
        • Kobayashi Y.
        • Kato K.
        • Bou-Gharios G.
        • Nakamura H.
        • et al.
        Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
        Int J Oncol. 2017; 50: 41-48
        • Yang C.Y.
        • Lin M.W.
        • Chang Y.L.
        • Wu C.T.
        • Yang P.C.
        Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
        Eur J Cancer. 2016; 57: 91-103
        • Tumeh P.C.
        • Harview C.L.
        • Yearley J.H.
        • Shintaku I.P.
        • Taylor E.J.
        • Robert L.
        • et al.
        PD-1 blockade induces responses by inhibiting adaptive immune resistance.
        Nature. 2014; 515: 568-571
        • Rizvi N.A.
        • Hellmann M.D.
        • Snyder A.
        • Kvistborg P.
        • Makarov V.
        • Havel J.J.
        • et al.
        Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
        Science. 2015; 348: 124-128
        • Wang C.
        • Yu X.
        • Wang W.
        A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
        Medicine (Baltimore). 2016; 95: e5539
        • Ries C.H.
        • Cannarile M.A.
        • Hoves S.
        • Benz J.
        • Wartha K.
        • Runza V.
        • et al.
        Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
        Cancer Cell. 2014; 25: 846-859
        • Mitchem J.B.
        • Brennan D.J.
        • Knolhoff B.L.
        • Belt B.A.
        • Zhu Y.
        • Sanford D.E.
        • et al.
        Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.
        Cancer Res. 2013; 73: 1128-1141